Dr. Manuel López Cabrera Bsc., PhD. (TRAUMdialysis founder partner):

Senior researcher at CSIC (Spanish Higher Council for Scientific Research);

Head of research group at the Center of Molecular Biology – Severo Ochoa. PhD in Biology and Immunology, with more than 30 years of experience in biomedical research.

Author of more than 140 scientific articles, 105 of them belonging to the first quartile in impact index, director of 9 doctoral theses in the last 10 years, author of 4 international patents in the area of product development in peritoneal dialysis.

Principal investigator and coordinator in 6 national and European research projects. Numerous R&D service contracts with the pharmaceutical industry and Biotechnology SMEs.

Focused on the study of the clinical implication of the cellular process of epithelial to mesenchymal transition (EMT) in two groups of pathologies: 1) Liver diseases associated with hepatocarcinoma induced by HCV and HBV. Pioneering the role of viral proteins in tumor development. 2) And mainly in the last two decades focused on pathophysiological processes of TMS in the peritoneal cavity associated with peritoneal dialysis, developing methods of isolation and cell culture of cells derived from peritoneum of patients, validated in vivo models, and identification of molecular therapeutic targets of the EMT process.

Recently also focused on the study of peritoneal post-surgical adhesions and peritoneal carcinomatosis associated with TMS. Expert and world leader in the study of peritoneal fibrosis and deterioration of the ultrafiltration process associated with chronic exposure to peritoneal dialysis fluids in patients with chronic renal failure.